Earnings call transcript: Zynex Q1 2025 earnings miss, stock drops 6.73%
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed significant challenges, including a revenue decline due to TRICARE payment suspension, increased competition, and regulatory hurdles. Despite cost-saving measures and long-term growth optimism, the lack of guidance for 2025, expected net loss, and unclear TRICARE resolution weigh negatively. The Q&A section underscored uncertainties, particularly around TRICARE payments, which are crucial for revenue recovery. The absence of clear management responses further adds to investor concerns. Given these factors, a negative stock price reaction is expected over the next two weeks.
Key Financial Performance
Net Revenue $26,600,000 (down from $46,500,000 in Q1 2024), primarily due to a temporary payment suspension from TRICARE and slowing order growth.
Device Revenue $11,900,000, part of the overall revenue decline attributed to TRICARE's payment suspension.
Supplies Revenue $14,700,000, also affected by the TRICARE payment suspension.
Gross Profit $18,200,000 (69% of revenue), down from $37,200,000 (80% of revenue in Q1 2024), due to lower revenue.
Sales and Marketing Expenses $16,900,000 (decreased by 28% from the previous year), primarily due to headcount reduction.
G&A Expenses $14,400,000, up from $13,300,000 last year.
Net Loss $10,400,000 ($0.33 per share), compared to a net income of $10,000 last year.
Adjusted EBITDA Loss of $11,800,000, compared to an adjusted EBITDA of $1,700,000 in Q1 2024.
Working Capital $40,000,000, indicating a strong balance sheet.
Cash on Hand Approximately $24,000,000.
Annual Savings from Staff Reduction Approximately $35,000,000, due to a 15% decrease in overall staff.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NICO Pulse Oximeter: The NICO pulse oximeter has completed all EMC and safety tests and is set for FDA submission, expected in May 2025. This product aims to provide accurate readings across all skin types and improve health equity.
TRICARE Payment Suspension: TRICARE has placed a temporary payment suspension while reviewing compliance with their policies. A response is expected by June 9, 2025.
New Revenue Opportunities: Zynex is focusing on diversifying revenue streams, including personal injury claims and promoting bracing products to prescribers.
Staff Reduction: In March 2025, Zynex reduced overall staff by approximately 15%, primarily in the corporate office, anticipating annual savings of about $35 million.
Sales Force Restructuring: The sales force is being refocused on new revenue opportunities, with a goal to improve productivity and drive growth.
Business Restructuring: Zynex is restructuring to operate without TRICARE business in a worst-case scenario, trimming unproductive areas to return to growth.
Long-term Revenue Goals: The company aims to generate revenue exceeding $800 million annually, with a focus on both pain management and patient monitoring divisions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
TRICARE Payment Suspension: TRICARE has placed a temporary payment suspension while reviewing compliance with their policies, impacting revenue significantly. The company is awaiting a response by June 9, which could restore payments.
Regulatory Challenges: The company is navigating regulatory challenges related to TRICARE and is preparing for FDA submission of the NICO pulse oximeter, which could face delays.
Staff Reductions: A 15% reduction in overall staff has been implemented to cut costs, which may affect operational capacity and morale.
Revenue Decline: Net revenue dropped to $26.6 million from $46.5 million year-over-year, primarily due to the TRICARE payment suspension and reduced sales rep productivity.
Market Competition: The company faces competitive pressures in the medical device market, particularly with the introduction of the NICO pulse oximeter, which aims to address biases in current technology.
Economic Factors: The overall economic environment and reimbursement changes are sensitive factors that could impact revenue recognition and operational performance.
Future Revenue Uncertainty: There is uncertainty regarding future revenue streams, especially if TRICARE payments do not resume, necessitating a restructuring of the business model.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
TRICARE Payment Suspension: Zynex is currently facing a temporary payment suspension from TRICARE while they review compliance with their billing practices. The company is restructuring to operate without TRICARE revenue in a worst-case scenario.
Cost Containment: Zynex has reduced overall staff by approximately 15%, primarily in the corporate office, which is expected to result in annual savings of approximately $35 million.
NICO Pulse Oximeter: Zynex is preparing to submit the NICO pulse oximeter for FDA approval, which is expected to be filed shortly. This product aims to provide accurate readings across all skin types and is anticipated to launch in 2026.
Sales Force Refocus: The company is refocusing its sales force on new revenue opportunities to drive growth, even without TRICARE patients.
Q2 Revenue Guidance: For Q2 2025, Zynex estimates revenue to be approximately $27 million, with an expected loss of $0.20 per share.
Long-term Revenue Goal: Zynex aims to generate revenue exceeding $800 million annually in the long term.
2025 Revenue Expectations: The company has not provided specific guidance for 2025 but is optimistic about growth opportunities beyond TRICARE.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Annual Savings from Staff Reduction: $35,000,000
Estimated Revenue for Q2 2025: $27,000,000
Expected EPS for Q2 2025: Loss of $0.20 per share
Net Revenue for Q1 2025: $26,600,000
Net Loss for Q1 2025: $10,400,000 or $0.33 per share
Cash on Hand: $24,000,000
Working Capital: $40,000,000
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give us more color into the conversation with TRICARE? Did you get a better sense of why they denied coverage?
A:At this time, we don’t have any more information that we can provide. The claims that we received from TRICARE for payment suspensions are fairly vague, so we just presented our compliance with their guidelines and policies.
Q:What got worse in Q1 compared to your previous update?
A:There’s a multitude of factors. We have ins and outs with payers all the time, and our revenue recognition is sensitive to those changes. We had a couple of those in Q1, and so we ended up a little short.
Q:Could you confirm that the first quarter revenue and guidance for the second quarter contain no payments from TRICARE?
A:That’s correct.
Q:If the outcome is positive, do you believe TRICARE will give you a lump sum payment that was due in the first quarter and the second quarter?
A:I don’t know that we’re positive on how it’ll come through, but they have told us that we would get reimbursed for those claims that haven’t been paid.
Q:If the outcome is negative, will you stop servicing the TRICARE patients?
A:We’re refocusing our sales force so that we will grow in other areas.
Q:If Nico is approved before the end of 2025, do you expect it to generate meaningful sales in 2026?
A:2026 is the year for revenue for Nico.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the specifics of the TRICARE payment suspension and the reasons behind it, stating that the claims were vague and they could not provide more information. Additionally, there was a lack of clarity on how TRICARE would handle reimbursements if the outcome is positive.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Agency argument
HC Wainwright
Mr Chairman
Officer Zynex
Policies conversation
President Zynax
Solutions Zynex
Wainwright end
Wainwright outcome
Wainwright question
Wainwright reason
Zynax Monitoring
Zynex Chief
Zynex HC
Zynex claim
Zynex couple
Zynex information
Zynex launch
Zynex today
amount revenue
answer star
area amount
area hour
argument claim
claim payment
color conversation
conversation payer
coverage
decision
evidence
guideline policy
payment Chief
payment suspension
star number
thing
ZYXI Transcript
Zynex, Inc. (ZYXI) Q3 2025 Earnings Call Prepared Remarks Transcript
Unknown11-18
The earnings call reveals significant financial challenges, including a drastic revenue decline, negative cash flow, and asset impairment. Despite efforts to stabilize, uncertainties from government investigations and debt obligations overshadow potential positive developments. The suspension of guidance and liquidity concerns further exacerbate the situation. With no clear resolution in sight and ongoing operational challenges, the stock is likely to experience a strong negative reaction in the short term.
Zynex, Inc. (ZYXI) Q2 2025 Earnings Call Transcript
Unknown7-31
The earnings call reveals significant challenges: a sharp revenue decline, ongoing FDA approval delays, and unresolved TRICARE payment issues. The restructuring efforts, while aimed at cost savings, are causing short-term disruptions. Despite a strong balance sheet, the net loss and declining gross profit raise concerns. Management's unclear responses on key issues further contribute to a negative sentiment. With a mid-cap stock, these factors likely result in a negative market reaction, estimated between -2% to -8%.
Earnings call transcript: Zynex Q1 2025 earnings miss, stock drops 6.73%
Unknown4-29
The earnings call revealed significant challenges, including a revenue decline due to TRICARE payment suspension, increased competition, and regulatory hurdles. Despite cost-saving measures and long-term growth optimism, the lack of guidance for 2025, expected net loss, and unclear TRICARE resolution weigh negatively. The Q&A section underscored uncertainties, particularly around TRICARE payments, which are crucial for revenue recovery. The absence of clear management responses further adds to investor concerns. Given these factors, a negative stock price reaction is expected over the next two weeks.
Zynex, Inc. (ZYXI) Q1 2025 Earnings Call Transcript
Unknown4-29
The earnings call highlights significant challenges: a 43% revenue decline, regulatory issues with TriCare, and operational inefficiencies. The lack of guidance and unclear management responses further exacerbate concerns. Although cost-saving measures and potential new product launches provide some optimism, the immediate outlook remains negative due to the unresolved TriCare suspension and expected net losses. The sentiment in the Q&A indicates uncertainty and skepticism among analysts, leading to a negative stock price prediction in the short term.
ZYXI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
